Study of Tocilizumab to Treat Polymyalgia Rheumatica

Disease- Specific Inclusion Criteria: Patients must meet the following inclusion criteria to be eligible for study entry: Diagnosed with polymyalgia rheumatica and enrolled within one month of diagnosis. Disease Specific Exclusion Criteria: Patients will be excluded from the study based on the following criteria: * Symptoms or diagnosis of temporal arteritis, including headache, jaw claudication, hyperesthesia of scalp, abnormal palpated temporal artery, visual disturbances, temporal artery biopsy positivity * Concurrent rheumatoid arthritis * Presence of rheumatoid factor and CCP * Other inflammatory arthritis or other connective tissue diseases, such as but not limited to systemic lupus erythematosus, systemic sclerosis, vasculitis, polymyositis, dermatomyositis, mixed connective tissue disease * Treatment of polymyalgia rheumatica with more than 20mg of daily prednisone or its equivalent at the time of screening * Treatment with more than 30mg of daily prednisone or its equivalent since diagnosis. Treatment with 30mg of daily prednisone or its equivalent since diagnosis for more than 2 weeks. * More than 4 weeks of corticosteroid therapy prior to enrollment * History of bowel perforation within the past five years. * Active diverticulitis. * Pre-existing or recent onset demyelinating disorders